Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion ... Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA ...

Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA ...

SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA ... a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic ...

2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research ...